Vitamin D Receptor Upregulation Promotes Ferroptosis-Related Salivary Gland Dysfunction in Female Mice

Study Background and Research Question

Salivary gland hypofunction, manifesting as xerostomia (dry mouth), is a prevalent clinical problem with significant impacts on oral health and quality of life. Epidemiological data indicate a disproportionate burden in women, particularly postmenopausal populations, but the underlying molecular mechanisms remain incompletely understood. Oxidative stress, driven by excessive reactive oxygen species (ROS), has been implicated in salivary gland dysfunction, but the precise cell death pathways and regulatory factors involved have not been fully elucidated. The reference study by Han et al. (2025) addresses whether ferroptosis, a form of iron-dependent cell death characterized by lipid peroxidation, contributes to salivary gland hyposecretion—specifically assessing the role of vitamin D receptor (VDR) upregulation in this process using a Sod1 knockout (SKO) mouse model [source_type: paper][source_link: https://doi.org/10.1016/j.freeradbiomed.2025.04.041].

Key Innovation from the Reference Study

The principal innovation of Han et al. lies in the identification of VDR as a positive regulator of ferroptosis in the context of salivary gland dysfunction. The study establishes a causal link between increased VDR expression and ferroptosis-specific gene signatures in female SKO mice, supporting the hypothesis that ferroptosis contributes to sex-specific salivary hyposecretion under chronic oxidative stress. Notably, the study provides mechanistic evidence that VDR directly enhances the expression of transferrin receptor (TFRC), a key facilitator of iron uptake and ferroptotic sensitivity, by binding to its predicted gene promoter. This regulatory axis connects endocrine signaling (via VDR) with the molecular machinery of ferroptosis, advancing our understanding of sex differences in oxidative stress responses [source_type: paper][source_link: https://doi.org/10.1016/j.freeradbiomed.2025.04.041].

Methods and Experimental Design Insights

Han et al. employ a robust combination of in vivo and in vitro approaches:

• Animal Model: Female and male Sod1 knockout (SKO) mice were used to model enhanced endogenous oxidative stress, leveraging the known function of Sod1 in superoxide detoxification.
• Salivary Flow Assessment: Stimulated saliva production was quantified, revealing significant hyposecretion in female SKO mice but not in males.
• Molecular Profiling: Transcriptomic analyses of salivary gland tissues highlighted upregulation of ferroptosis-related genes and VDR specifically in female SKO mice.
• Cell Culture Experiments: Human A253 salivary gland epithelial cells were exposed to 4-nitroquinoline N-oxide (4NQO), a superoxide inducer, to recapitulate oxidative stress and monitor gene expression changes.
• Gene Overexpression: VDR was overexpressed in A253 cells to assess its impact on TFRC expression and ferroptosis sensitivity.
• Promoter Binding Analysis: Chromatin immunoprecipitation (ChIP) and promoter assays confirmed VDR's direct interaction with the TFRC promoter.

These methodological choices enabled a rigorous dissection of the causal pathway linking VDR upregulation to ferroptosis and hyposecretion.

Protocol Parameters

• assay | saliva flow rate quantification | μL/min | distinguishes sex- and genotype-specific secretion deficits | identifies phenotype in SKO mice | paper
• assay | 4NQO exposure in A253 cells | 10 μM, 24 h | models oxidative stress for gene expression profiling | recapitulates ROS-driven damage | paper
• assay | VDR overexpression via plasmid transfection | 48 h | tests regulatory impact on TFRC and ferroptosis genes | defines VDR function in vitro | paper
• assay | ChIP-qPCR for VDR binding | antibody concentration and primer sets per protocol | confirms direct TFRC promoter interaction | mechanistic validation | paper
• assay | lipid peroxidation marker quantification (e.g., 4HNE, MDA) | tissue homogenates, standard curves | tracks ferroptosis progression in vivo | correlates with hyposecretion phenotype | paper

Core Findings and Why They Matter

The study's central findings can be summarized as follows:

• Sex-specific Ferroptosis Activation: Only female, not male, SKO mice exhibited pronounced salivary hyposecretion, elevated VDR expression, and a ferroptosis gene signature in salivary glands [source_type: paper][source_link: https://doi.org/10.1016/j.freeradbiomed.2025.04.041].
• VDR-Ferroptosis Axis: VDR overexpression in A253 cells upregulated TFRC and ferroptosis-associated genes, and ChIP assays confirmed VDR binding at the TFRC promoter, establishing a direct regulatory pathway.
• Oxidative Stress and Lipid Peroxidation: Female SKO mice displayed increased markers of lipid peroxidation (e.g., 4HNE, MDA) and cell death consistent with ferroptosis [source_type: paper][source_link: https://doi.org/10.1016/j.freeradbiomed.2025.04.041].

These data implicate the VDR–TFRC–ferroptosis axis as a key driver of salivary gland dysfunction under chronic oxidative stress, particularly in females. The findings suggest that therapeutic inhibition of lipid peroxidation and ferroptosis may ameliorate glandular hypofunction in relevant clinical contexts, including aging and autoimmune syndromes.

Comparison with Existing Internal Articles

Recent internal resources provide complementary perspectives on the experimental and translational use of ferroptosis inhibitors:

• The article "Liproxstatin-1: Potent Ferroptosis Inhibitor for Advanced..." details how Liproxstatin-1 enables precise dissection of iron-dependent cell death mechanisms in renal, hepatic, and glandular models, including workflows involving GPX4-deficient cells. This aligns with the current study's focus on lipid peroxidation and ferroptosis in secretory tissues [source_type: workflow_recommendation][source_link: https://fasc-terminal-tripeptide.com/index.php?g=Wap&m=Article&a=detail&id=15794].
• "Liproxstatin-1: Strategic Ferroptosis Inhibition in Translational Models" explores the broader translational potential of ferroptosis inhibition in oxidative stress–driven glandular dysfunction, directly referencing VDR-mediated ferroptosis as a mechanistic target—closely paralleling the findings of Han et al. [source_type: workflow_recommendation][source_link: https://ferritin-heavy-chain-fragment.com/].
• The article "Liproxstatin-1 (SKU B4987): Data-Driven Solutions for Fer..." provides validated protocols for inhibition of lipid peroxidation and cell death assays, supporting the technical approaches described in the reference study.

Together, these resources reinforce the practical value of small molecule ferroptosis inhibitors for dissecting and potentially ameliorating secretory gland dysfunction.

Limitations and Transferability

Han et al.'s study is notable for its mechanistic rigor but is subject to several limitations:

• Species and Sex-Specificity: Findings are based on mouse models and human cell lines, with effects observed predominantly in females. Translational relevance to human males or other tissues may require further validation.
• Model Specificity: The use of SKO mice models high oxidative stress, which may not capture all clinical etiologies of salivary hyposecretion (e.g., autoimmune, iatrogenic, or idiopathic dry mouth).
• No Direct Inhibitor Testing: While the study documents ferroptosis, it does not directly assess the impact of pharmacological ferroptosis inhibition (e.g., with Liproxstatin-1) on salivary gland function.

Nevertheless, the mechanistic insights are likely transferable to other models of oxidative stress–induced secretory dysfunction, and the regulatory axis identified (VDR–TFRC–ferroptosis) offers targets for experimental intervention.

Research Support Resources

Researchers aiming to interrogate ferroptosis in secretory gland models or to validate the role of lipid peroxidation in tissue dysfunction can leverage potent ferroptosis inhibitors such as Liproxstatin-1 (SKU B4987) [source_type: product_spec][source_link: https://www.apexbt.com/liproxstatin-1.html]. Liproxstatin-1 is well-characterized for its nanomolar inhibition of ferroptotic cell death and compatibility with GPX4-deficient and oxidative stress models [source_type: workflow_recommendation][source_link: https://fasc-terminal-tripeptide.com/index.php?g=Wap&m=Article&a=detail&id=15794]. For protocol guidance and translational insights, consult the detailed workflows in the referenced internal articles above. APExBIO provides comprehensive product specifications and application notes to support rigorous ferroptosis research in diverse organ systems.